Annexin

Promising signals of effect in Annexin's RVO-study

Retrieved on: 
Friday, August 11, 2023
Retina, Comment, Medicine, Diagnosis, Ophthalmology, Ranibizumab, Visual acuity, Patient, Standard of care, RVO, Safety, Disease, Pharmaceutical industry, Annexin

A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study.

Key Points: 
  • A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study.
  • The evaluation confirmed an unexpectedly long duration of effect with a single dose of standard of care anti-VEGF treatment in two of five treated patients.
  • The unmasking showed that the two patients with potential signals of effect had received ANXV.
  • No clear signals of effect were observed in the other patients in the study where two had received ANXV and one had received placebo.

Promising signals of effect in Annexin's RVO-study

Retrieved on: 
Friday, August 11, 2023
Retina, Comment, Medicine, Diagnosis, Ophthalmology, Ranibizumab, Visual acuity, Patient, Standard of care, RVO, Safety, Disease, Pharmaceutical industry, Annexin

A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study.

Key Points: 
  • A group of leading independent US ophthalmologists has conducted an evaluation of the available information from patients treated so far in the placebo-controlled study.
  • The evaluation confirmed an unexpectedly long duration of effect with a single dose of standard of care anti-VEGF treatment in two of five treated patients.
  • The unmasking showed that the two patients with potential signals of effect had received ANXV.
  • No clear signals of effect were observed in the other patients in the study where two had received ANXV and one had received placebo.